CompletedNot Applicable

Impact of Pharmaceutical Care on Drug-related Problems in Patients With Parkinson's Disease

Thailand80 participantsStarted 2022-03-11

Plain-language summary

The aim of this study is to evaluate the impact of pharmaceutical care on the number of drug-related problems, clinical outcomes and quality of life of patients with Parkinson's disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18 years or older
✓. Diagnosed with idiopathic Parkinson's disease according to the UK Parkinson's disease Society Brain Bank Criteria for at least 3 years
✓. Modified Hoehn and Yahr stage 2-4
✓. Patient had received at least one of antiparkinsonian drugs the following: levodopa, MAO-B inhibitors, dopamine agonists, COMT inhibitors, amantadine, and trihexyphenidyl
✓. Patient has given a written informed consent to participate in the study. If the patients are unable to give an informed consent, it must be obtained from the caregiver.

Exclusion criteria

✕. Patient is unable to communicate via telephone or mobile phone or internet.
✕. Patient who is terminal illness
✕. Patient who is bed ridden
✕. Patient with other movement disorders include corticobasal syndrome, multiple system atrophy, progressive supranuclear palsy and essential tremor
✕. Moderate to severe dementia as evidenced by Mini Mental State Examination (MMSE) or Thai Mental State Examination (TMSE) less than 20 and without the caregiver
✕. Patient who is planning to undergo surgery or have a history of surgical treatment for Parkinson's disease such as pallidotomy, thalamotomy, or deep brain stimulation
✕. Patient with hearing impairments which affects communication via telephone or electronic media
✕. Unable to communicate Thai language

What they're measuring

Change in the total number of drug-related problems related to all drugs

Timeframe: 24 weeks

Trial details

NCT IDNCT05410210

SponsorMahidol University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-02

View on ClinicalTrials.gov More Parkinson Disease trials